Tumor biology and anticancer therapy: from mechanism papers to pivotal readouts and launches.
Resident tissue macrophages establish a selenium-rich microenvironment at the pancreatic tumor border and protect invasive tumor cells from ferroptosis by transferring the selenium transporter Selenop to epithelial-mesenchymal-transition-high (EMThi) cancer cells.
Why it matters: New mechanism showing macrophage-transferred Selenop shields pancreatic cancer cells from ferroptosis.
Newly diagnosed glioblastoma patients show altered gut bacteria and fungi: rectal-swab sequencing of 23 patients and 23 controls found both communities more diverse in patients, with Lachnospiraceae and Ruminococcaceae depleted and Methanobrevibacter and Nakaseomyces glabratus enriched. In tumor tissue, higher density of Iba1-positive myeloid cells predicted longer survival independent of age, performance status and resection extent (hazard ratio 0.82 per percentage point, 95% CI 0.67–0.99). The authors propose the myeloid compartment as the interface linking gut and tumor findings.
Why it matters: First characterization of the gut mycobiome in glioblastoma, linking gut taxa to intratumoral myeloid cells and survival.
An expanded DNA methylation-based sarcoma classifier (v13.1) was trained on 4377 methylation profiles covering 116 tumor sub-classes, 4 control groups and 93 distinct methylation classes, and validated in 1547 mesenchymal tumors from four independent cohorts. Five-fold nested cross-validation yielded 98% class-level accuracy with a Brier score of 0.017. Predictions were obtained in 73% of validation cases, 91% matched the histopathology diagnosis, and 6% of inconclusive or ambiguous cases gained a definitive molecular diagnosis or reclassification.
Why it matters: A larger, validated methylation classifier broadens molecular diagnosis options for diagnostically difficult mesenchymal tumors.
The UK's MHRA has approved lurbinectedin for the treatment of adults with extensive-stage small cell lung cancer. The MHRA says it will continue to closely monitor the drug's safety and effectiveness and track its clinical performance on an ongoing basis.
Why it matters: New regulatory approval of an oncology drug by the UK MHRA.
Migrasomes have a previously undescribed role in antitumor immunity during tumor metastasis, according to work by Yu Li and Jiang Dong's team published in Nature Immunology. Tumor metastasis, the main cause of cancer death, lets malignant cells spread to distant sites and often escape immune clearance. The study shows that migrasome-mediated antigen release during metastasis activates antitumor immunity, with dendritic cells capturing the released antigens and activating cytotoxic T lymphocytes to attack cancer cells.
Why it matters: Assigns a new immunological function to migrasomes in a top immunology journal.
Loss of SETDB1 in hepatocellular carcinoma activates the cGAS-STING pathway, driving CXCL12 expression and inducing the formation of tertiary lymphoid structures within tumors. These structures recruit B cells, T cells and dendritic cells, local immune hubs that help the body sustain recognition and attack of tumor cells. The work identifies a molecular signal that controls TLS formation, which normally does not arise abundantly in tumors and whose regulation had been unclear.
Why it matters: It identifies SETDB1-cGAS-STING-CXCL12 as a molecular switch controlling tertiary lymphoid structure formation in liver cancer.
Anito-cel, a d-domain CAR T cell targeting BCMA, showed a favorable safety profile and preliminary efficacy in a phase 1 clinical trial for refractory or relapsed multiple myeloma. The study assessed the safety, tolerability, and antitumor activity of anito-cel at escalating dose levels. The findings support further clinical development of this therapy in patients with relapsed/refractory multiple myeloma.
Why it matters: Trending: 21 ten-thousand views.
A study found that SCRMP-mediated SUMOylation of CSNK2B promotes DNA damage repair, causing cisplatin resistance in small cell lung cancer. Mechanistic work showed that SUMOylated CSNK2B interacts more strongly with DNA repair proteins, and knocking down SCRMP or inhibiting CSNK2B reverses the resistance. DOI: 10.1126/scitranslmed.aea5653.
Why it matters: The finding links an RNA-mediated modification to cisplatin resistance in small cell lung cancer.
A study finds that the CXCL1-CXCR2 signaling pathway drives cancer cell growth in leptomeningeal metastasis and affects the response to radiation therapy.
Why it matters: Reports a signaling pathway affecting growth and radiotherapy response in leptomeningeal metastasis.
Enterocolitis after BCMA CAR-T cell therapy in patients with multiple myeloma is driven not only by plasma cell and B cell depletion but by expansion of cytotoxic CAR-T cells and coordinated dysregulation across intestinal compartments, a multimodal analysis shows. Mucosal CAR-T cells persist at the inflammation site. The findings support JAK inhibitors as a potential treatment for this complication.
Why it matters: Redefines the mechanism of BCMA CAR-T enterocolitis and points to JAK inhibitors as a treatment option.
Mammography use among males with pathogenic BRCA1/2 variants is low: only 19% of 810 BRCA+ males had a documented mammogram, and just 16% of 562 age-eligible males completed one. No male breast cancer was detected in 97 screening mammograms, while symptom-driven mammograms found MBC in 29% of 59 BRCA+ versus 21% of 228 BRCA- males (p=0.219). Nearly all MBC in both groups was diagnosed after symptoms, often at advanced stages, with 55% of 22 BRCA+ tumors node positive.
Why it matters: Quantifies very low screening mammography uptake in BRCA+ males despite elevated hereditary breast cancer risk.
Deleting ZMYND8 lifts the block it imposes on IL-2R–STAT5 signalling in CD8+ T cells, restoring p300-mediated transcriptional activation of Il2ra and overriding terminal exhaustion. Loss of ZMYND8 pushed the cells toward effector-like states and markedly enhanced both antiviral and antitumour immunity, identifying a druggable route to reclaim exhausted T cell function.
Why it matters: Identifies ZMYND8 as a checkpoint on IL-2 signalling that enforces CD8+ T cell exhaustion.
Type 2 deiodinase (DIO2), the enzyme converting T4 to T3, is a conserved marker of cancer-associated fibroblasts (CAF) across thyroid cancer and six additional solid tumor types, and is enriched in myofibroblastic CAF. Elevated DIO2 expression correlated with worse overall survival in pancreatic and bladder cancers, while thyroid cancer showed an inverse association linked to loss of epithelial DIO2 during dedifferentiation. In a TPO-CreERT2/BrafV600E/Trp53-deficient mouse model, Dio2 loss in the tumor microenvironment significantly reduced tumor growth, and D2 activity was suppressed by cefuroxime and lenvatinib.
Why it matters: Identifies DIO2 as a CAF-restricted, druggable target conserved across solid tumors, with preclinical evidence of tumor suppression.
A design strategy for bitopic kinase inhibitors used systematic analysis of ligand choice, linkage vector and linker length. Applying it to ABL1 and EGFR produced bitopic inhibitors, among them an ABL1 inhibitor with enhanced activity against resistance mutations and reduced off-target toxicity. The work offers a generalizable route to bitopic inhibitor design.
Why it matters: Provides a generalizable design framework yielding an ABL1 inhibitor active against resistance mutations with less off-target toxicity.
Pancreatic ductal adenocarcinoma metastases in the liver that lack the enzyme needed to synthesize serine can reprogram hepatocytes to produce this amino acid. The serine supplied by hepatocytes promotes tumour growth and survival, identifying a metabolic interaction between liver cells and metastatic PDAC.
Why it matters: It identifies hepatocyte-supplied serine as a mechanism supporting liver metastasis of PDAC.
A study shows that an AI-designed IL-21 mimetic can convert transient responses to KRAS inhibitors into durable remissions in pancreatic cancer through CD4 T cells, independent of CD8 T cells and tumor MHC class I expression.
Why it matters: The study reveals how an AI-designed IL-21 mimetic turns CD4 T cells into mediators of KRAS inhibitor efficacy in pancreatic cancer, offering a new angle on overcoming resistance.
A modeling analysis of the NHS-Galleri trial projects that the reduction in stage IV diagnoses seen after two annual multi-cancer early detection screening rounds could yield 66.3 potential five-year life-years in the trial intervention cohort, or 466 per million people screened annually (95% interval 190-743). Intervention and control arms recorded 180 versus 239 stage IV diagnoses across ten evaluable cancers, with colorectal, lung and esophageal cancers accounting for 79% of the net projection. The authors stress this conditional estimate is not evidence of mortality reduction, and longer follow-up is needed.
Why it matters: Translates NHS-Galleri's stage IV shift into projected life-years per million screened, clarifying what the screening signal may or may not mean.
NEJM published a study (Vol 395, Issue 14, pp 1374-1386, 2026-10-08) evaluating the effect of multicancer early detection (MCED) screening on late-stage cancer diagnosis. Only citation information is currently available; the abstract and full text were not provided through the feed.
Why it matters: The abstract and full text are not yet available through the feed.
Esophageal cancer detection through noncontrast computed tomography is enhanced by a new artificial intelligence tool called Esophageal AI-Guided malignant Lesion Evaluation. In a large-scale study, the tool achieved high sensitivity and specificity across diverse settings.
Why it matters: It points to CT-based AI screening as a route to wider esophageal cancer detection.
The PATHFINDER 2 study evaluated the safety and performance of a blood-based multi-cancer early detection test in an intended-use population of more than 35,000 participants aged 50 years or older. It reports outcomes on how the test performs when used prospectively in people without a prior cancer diagnosis. The findings add interventional evidence on safety and performance in the intended-use setting.
Why it matters: Large interventional evidence on a multi-cancer early detection blood test in its intended-use population.
